Download Image
    
Share
  
Post
Ropeginterferon alfa-2b for COVID-19
1 study with 132 patients
Hospital Icon Control
Hospital Icon Ropeginterferon alfa-2b Serious Outcome Risk
Significantly lower risk for ventilation.
COVID-19 Ropeginterferon alfa-2b studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -3% Mortality -3% RCTs -3% Early -3% Favorsropeginterferon alfa-2b Favorscontrol
Ropeginterferon Alfa-2b is a long-acting, mono-pegylated recombinant Type I interferon biologic administered via subcutaneous injection.
May 21
2024
 Liu et al., Infectious Diseases and Therapy, doi:10.1007/s40121-024-00992-5 A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19
90% lower ventilation (p=0.04), 3% higher need for oxygen therapy (p=1), and 4% improved recovery (p=1). RCT 132 hospitalized moderate COVID-19 patients in Taiwan showing higher rates of viral clearance or discharge by day 11 with ropeginterferon alfa-2b. The ropeginterferon alfa-2b group also showed higher rates of improvement in lung infil..